Geneos Wealth Management Inc. Has $4.85 Million Stock Position in Elanco Animal Health Incorporated $ELAN

Geneos Wealth Management Inc. lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3,358.1% in the first quarter, HoldingsChannel reports. The fund owned 202,747 shares of the company’s stock after buying an additional 196,884 shares during the period. Geneos Wealth Management Inc.’s holdings in Elanco Animal Health were worth $4,852,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. NewEdge Advisors LLC raised its holdings in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the last quarter. Root Financial Partners LLC boosted its stake in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $41,000. Torren Management LLC acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $46,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Elanco Animal Health by 43.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after buying an additional 938 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the business’s stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ELAN. Citigroup increased their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. TD Cowen upped their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. JPMorgan Chase & Co. raised their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus price target of $28.55.

Elanco Animal Health Trading Up 1.6%

ELAN opened at $25.95 on Friday. The stock has a market capitalization of $12.96 billion, a P/E ratio of -51.90, a P/E/G ratio of 1.67 and a beta of 1.68. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $13.39 and a 12 month high of $27.72. The firm’s fifty day simple moving average is $23.58 and its 200 day simple moving average is $23.87.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter last year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.